Tackling the epidemic of chronic liver disease- moving towards earlier detection

Lead Research Organisation: University of Southampton
Department Name: Community Clinical Sciences

Abstract

Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
 
Description National Liver Strategy
Geographic Reach Local/Municipal/Regional 
Policy Influence Type Participation in advisory committee
Impact Membership of advisory Group on prevention of Chronic liver disease which informed the development of the NAtional Liver Disease Startegy for England & Wales
 
Description Senior Lecturership
Amount £250,000 (GBP)
Organisation University of Southampton 
Sector Academic/University
Country United Kingdom
Start 10/2008 
End 09/2013
 
Description biomarker validaiton n HCV-HIV cohort 
Organisation University of San Francisco
Country United States 
Sector Academic/University 
PI Contribution clinical epidemiology and diagnostic test expertise. Analysis of data Collaboration on wrtiing papers
Collaborator Contribution Working togther on a cohort of people with HCV HIV co -infection to determine the performance of a panel of Biomarkers in predictiing liver fibrosis and clinical utcomes
Impact conference abstract
Start Year 2009
 
Description epidemiology of liver disease & Biomarker research 
Organisation University College London
Department Institute of Liver and Digestive Health
Country United Kingdom 
Sector Academic/University 
PI Contribution provide content expertise in diagnostic tests and prognostic tests especially in liver disease. Taking forward research conducted in doctorate
Collaborator Contribution working together to apply for grant funding for rseaerch into biomarkers in liver disease clinical and research expertise
Impact Public health and hepatology
Start Year 2008
 
Description external validation of biomarker panel 
Organisation Centers for Disease Control and Prevention (CDC)
Department Division of Viral Hepatitis
Country United States 
Sector Public 
PI Contribution analysis of data writing draft of paper commenting on subsequent drafts
Collaborator Contribution Provision of serum samples Comment son drafts of paperwprking together to conduct an external validation of ELf panel in paediatric populaion in Italy
Impact publication JVH 2010
Start Year 2006
 
Description external validation of biomarker panel 
Organisation University of Florence
Department Department of Internal Medicine
Country Italy 
Sector Academic/University 
PI Contribution analysis of data writing draft of paper commenting on subsequent drafts
Collaborator Contribution Provision of serum samples Comment son drafts of paperwprking together to conduct an external validation of ELf panel in paediatric populaion in Italy
Impact publication JVH 2010
Start Year 2006
 
Description external validation of biomarker panel 
Organisation University of Florence
Country Italy 
Sector Academic/University 
PI Contribution Using serum samples of biomarker panel were Analysis of data Interpretation fo data Writing of paper for publication
Collaborator Contribution working togther to conduct an external validaiton study in paediatric population. Porvided serum samples, data. Help to write a scientific paper published in peer reviewed juornal
Impact Nobili V , Parkes J, Bottazzo G, et al Performance of ELF serum markers in predicting fibrosis stage in pediatric non-alcoholic fatty liver disease. Gastroenterology. 2009;136:160-7.
Start Year 2007
 
Title Enhanced Liver Fibrosis (ELF) Panel 
Description MRC funding for Doctorate provided (1) evidence of External validation of ELF panel biomarkers in predicting liver fibrosis on biopsy, and (2) prediction of clinical outcomes in people with chronic liver disease. This added substantive evidence of performance of this biomarker panel and contributed to the commercialisation and CE marking of the panel. 
Type Diagnostic Tool - Non-Imaging
Current Stage Of Development Small-scale adoption
Year Development Stage Completed 2009
Development Status Under active development/distribution
Impact The ELF panel is presently available for use in patients with Chronic liver disease in the NHS. Provide evidence to Support the application by Siemens for FDA approval in USA 
 
Description Presentation to Wessex Medical Research Charity 
Form Of Engagement Activity A talk or presentation
Part Of Official Scheme? No
Primary Audience Public/other audiences
Results and Impact 60 people attended an annual meeting of a local charity that raises money for medical research. I gave a presentation of the work completed on biomarkers in liver disease conducted during my MRC Fellowship, followed by questions and dscussion afterwards.

This seemed to be well recieved and raised the profile of liver disease research both locally and nationally
Year(s) Of Engagement Activity 2011
 
Description newspaper article 
Form Of Engagement Activity A magazine, newsletter or online publication
Part Of Official Scheme? No
Primary Audience Media (as a channel to the public)
Results and Impact article on biomarker in liver disease for local press

wider knowledge in lay and professional audeinces of biomarker panel in prediciting liver fibrosis ,& clinical outcomes
Year(s) Of Engagement Activity 2007